Rhapsido (Remibrutinib)

Rhapsido (remibrutinib) is a kinase inhibitor used for the treatment of chronic spontaneous urticaria (CSU) in adult patients who remain symptomatic despite H1 antihistamine treatment.

Limitations of Use: This oral therapeutic drug is not indicated for the treatment of other forms of urticaria.

Recommended Dosage:
The recommended dosage of Remibrutinib is 25 mg taken orally twice daily with or without food. Swallow Remibrutinib tablet whole with water. It is not advisable to split, crush, or chew Remibrutinib tablets. If a dose or doses of Remibrutinib are missed, skip the missed dose, and take the next dose at its regularly scheduled time. Do not take an extra dose(s) of Remibrutinib to make up for a missed dose(s).

• Treatment with Remibrutinib may increase the risk of bleeding, particularly in those taking anticoagulants or antiplatelet drugs. Caution is required during surgery or invasive procedures. Monitor for symptoms such as nosebleeds, unusual bruising, or blood in stool, and seek medical attention immediately if they occur.
• Patients receiving Remibrutinib 25 mg should avoid live vaccines while on treatment and for some time after completion. The oral drug can reduce the immune response and may increase infection risk. Consult your clinician before any vaccination to ensure safety and to consider inactivated or non-live alternatives if required.
• This therapeutic drug may harm an unborn baby, so avoid its use during pregnancy unless absolutely required. Women of childbearing age should use effective contraception during treatment and for a period after stopping, as advised by their clinician. Always consult a doctor before planning a pregnancy.
• It is unknown whether this drug passes into breast milk. To avoid potential risks to the nursing infant, breastfeeding is not recommended during therapy and for a period after the final dose. Discuss safer feeding alternatives with your doctor before treatment.
• Patients with moderate to severe liver impairment may experience higher exposure to this drug. This may increase the risk of side effects. Monitor liver function regularly. Dosage adjustments or careful supervision may be needed based on clinical condition and physician recommendations to ensure safe treatment.
• The safety and efficacy of Remibrutinib 25 mg tablet in children have not been established. Use in pediatric patients is not recommended unless prescribed by a specialist under strict monitoring. Clinical data are limited, and further studies are needed to confirm the appropriate dosage and long-term safety.

What documents are required to import RHAPSIDO to India?

RHAPSIDO (remibrutinib) tablet can be imported by patients or government hospitals in the name of the patients only.
The following documentation is required to import the product:

• A valid prescription from a qualified doctor.
• Patients diagnostic reports
• Patient ID proof (issued by the government of India)

How does the order get confirmed?

The order will be confirmed only after the receipt of:

• A valid prescription from the Doctor
• Import permit if applicable

Is RHAPSIDO available in India?

RHAPSIDO (remibrutinib tablets) is a (prescription drug, prescription medication, or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.

IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is the facilitator, providing input

• On the availability of Rhapsido in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Pune, etc.)
• On availability in Gulf countries (Bahrain, Oman, Qatar, Kuwait, Iraq, Saudi Arabia, and the UAE).
• Medicine Price.
• Finding Genuine and reliable sources from the USA, Canada, Europe, and Australia
• Ensuring 100% transparency.

RHAPSIDO can be made available to patients, doctors, and hospitals in Mumbai, Goa, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, and Pune, and other cities in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and an import permit.

IPN (Indian Pharma Network) can facilitate the supply of RHAPSIDO (prescription medicines) to all locations in the world and India after fulfilling the legal requirements (if applicable).

Please contact +91-9310090915 | Toll-Free Number: 1800-889-1064 or write us at info@indianpharmanetwork.in for Rhapsido tablet 25 mg price in India.

We guarantee quality and delivery anywhere in the world as per the buyer’s requirements.

Indian Pharma Network can source RHAPSIDO (Cancer Treatment Medicines) from across the globe and can supply. Indian Pharma offers its customers worldwide access to the best available treatment.

Indian Pharma Network (IPN) can dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient’s address only from New Delhi, India.

What is the Generic Name for the trade name drug Rhapsido®?

Remibrutinib is the Generic Name for the trade name drug Rhapsido®.

What is the Manufacturer’s Name of Rhapsido®?

Rhapsido® is manufactured by Novartis Pharmaceuticals Corporation.

Is Rhapsido approved by the FDA?

Yes. Rhapsido is approved by the FDA. date of first approval: September 30, 2025.

What is the dosage and form of Rhapsido® supplied?

Rhapsido is supplied as Tablets: 25 mg of Remibrutinib for oral use.

What are the most common side effects of Rhapsido® tablet?

The most commonly reported side effects of Rhapsido® are headache, asopharyngitis, bleeding, nausea and abdominal pain.

How much does Rhapsido® tablet 25 mg cost in India?

Rhapsido® is not yet approved in India. However, patients in India can legally access it through the provision called the Named Patient Program (NPP). Rhapsido prices may fluctuate over time because of market dynamics and regulatory changes. For the most transparent and latest Rhapsido tablet 25 mg cost in India, please call/WhatsApp +91 98104 69557 or send an email to info@indianpharmanetwork.in.

Can Rhapsido® tablets 25 mg be available in SAARC countries?

Apart from Gulf countries, Rhapsido® 25 mg can be accessed through import provisions like the Named Patient Program (NPP) in SAARC countries (India, Afghanistan, Maldives, Nepal, Bangladesh, Bhutan, Pakistan, and Sri Lanka). Indian Pharma Network (IPN) can help facilitate the legal supply of Rhapsido® tablet in these countries. We help provide legal access to this therapeutic drug through our reliable channels.

Is it safe to buy Rhapsido® 25 mg tablets online in India?

Yes, one can buy Rhapsido 25 mg tablet online in India at the lowest price from the Indian Pharma Network (IPN) if this medicinal product is not yet registered or available in their country. We can help facilitate the legal supply of Rhapsido® tablet through legal channels.

What are the storage conditions of Rhapsido® 25 mg tablets?

Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C to 30°C (59°F to 86°F). Dispense and store in the original container to protect from moisture.